Sudeep Pharma Stock Price Today (NSE: SUDEEPPHRM)
Fundamental Score
Sudeep Pharma Share Price Live NSE/BSE & Institutional Fundamental Analysis
Sudeep Pharma share price today is ₹728.20, up +0.00% on NSE/BSE as of 1 December 2025. Sudeep Pharma (SUDEEPPHRM) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹8.23K (Cr). The 52-week high for SUDEEPPHRM share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 59.31x, SUDEEPPHRM is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 32.77% and a debt-to-equity ratio of 0.28.
Sudeep Pharma Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Sudeep Pharma Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Sudeep Pharma Share Price: A Conservative Value Investor's Perspective
The pharmaceutical sector, while generally defensive, requires careful scrutiny. Increased regulatory oversight and fluctuating raw material costs create inherent business risks. This analysis examines the recent performance of Sudeep Pharma share price from a conservative value investing standpoint, prioritizing capital preservation above all else. With a current market price of ₹728.2 and a PE ratio of 59.31, our initial assessment focuses on whether this valuation reflects underlying fundamentals.
A key metric for us is Return on Capital Employed (ROCE). Sudeep Pharma's ROCE of 35.65% is undoubtedly impressive. This high ROCE signals efficient capital allocation and suggests the company is generating substantial profits relative to the capital invested. Consistently high ROCE, when sustained over extended periods, can be a strong indicator of a company's economic moat – its ability to protect its profitability from competitors. However, we will assess if this ROCE is sustainable and if competitive pressures could erode these returns.
Compared to sector peers, the valuation warrants deeper inspection. For instance, consider
Mankind Pharma Ltd. While we won't delve into specific management quality assessments here, a comprehensive analysis would compare the leadership's track record in capital allocation, risk management, and corporate governance across both companies. Differences in management quality can justify valuation disparities, even amongst seemingly similar businesses.From a capital safety perspective, the high PE ratio requires further investigation. While the 35.65% ROCE is encouraging, it needs to be balanced against the relatively high valuation. We would look for strong earnings growth visibility to justify the multiple. This analysis forms part of a more extensive, 80-parameter fundamental audit that has been verified by Sweta Mishra, ensuring a comprehensive and rigorous evaluation of the company's financials and operations. We are observing the data and drawing no specific investment conclusions.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Sudeep Pharma Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SUDEEPPHRM across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Strong Return on Equity (32.77%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (35.65%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Consistent Growth Track Record (32.48% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (50.39% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.28)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (27.51x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Premium Valuation Risk (P/E: 59.31x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Weak Earnings Growth (-35.52% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Sudeep Pharma Financial Statements
Comprehensive financial data for Sudeep Pharma including income statement, balance sheet and cash flow
About SUDEEPPHRM (Sudeep Pharma)
Sudeep Pharma (SUDEEPPHRM) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹8.23K (Cr). Sudeep Pharma has delivered a Return on Equity (ROE) of 32.77% and a ROCE of 35.65%. The debt-to-equity ratio stands at 0.28, reflecting the company's capital structure. Investors tracking SUDEEPPHRM share price can monitor key metrics including P/E ratio, promoter holding of 76.15%, and quarterly earnings growth.
Company Details
SUDEEPPHRM Share Price: Frequently Asked Questions
What is the current share price of Sudeep Pharma (SUDEEPPHRM)?
As of 01 Dec 2025, 04:21 pm IST, Sudeep Pharma share price is ₹728.20. The SUDEEPPHRM stock has a market capitalisation of ₹8.23K (Cr) on NSE/BSE.
Is SUDEEPPHRM share price Overvalued or Undervalued?
SUDEEPPHRM share price is currently trading at a P/E ratio of 59.31x, compared to the industry average of 31.77x. Based on this relative valuation, the Sudeep Pharma stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of SUDEEPPHRM share price?
The 52-week high of SUDEEPPHRM share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Sudeep Pharma share price?
Key factors influencing SUDEEPPHRM share price include quarterly earnings growth (Sales Growth: N/A%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Sudeep Pharma a good stock for long-term investment?
Sudeep Pharma shows a 5-year Profit Growth of 50.39% and an ROE of 32.77%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.28 before investing in SUDEEPPHRM shares.
How does Sudeep Pharma compare with its industry peers?
Sudeep Pharma competes with major peers in the Pharmaceuticals. Investors should compare SUDEEPPHRM share price P/E of 59.31x and ROE of 32.77% against the industry averages to determine competitive standing.
What is the P/E ratio of SUDEEPPHRM and what does it mean?
SUDEEPPHRM share price has a P/E ratio of 59.31x compared to the industry average of 31.77x. Investors pay ₹59 for every ₹1 of annual earnings.
How is SUDEEPPHRM performing according to Bull Run's analysis?
SUDEEPPHRM has a Bull Run fundamental score of 45.4/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does SUDEEPPHRM belong to?
SUDEEPPHRM operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Sudeep Pharma share price.
What is Return on Equity (ROE) and why is it important for SUDEEPPHRM?
SUDEEPPHRM has an ROE of 32.77%, which indicates excellent management efficiency. ROE measures how efficiently Sudeep Pharma generates profits from shareholders capital.
How is SUDEEPPHRM debt-to-equity ratio and what does it indicate?
SUDEEPPHRM has a debt-to-equity ratio of 0.28, which indicates conservative financing with low financial risk.
What is SUDEEPPHRM dividend yield and is it a good dividend stock?
SUDEEPPHRM offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Sudeep Pharma shares.
How has SUDEEPPHRM share price grown over the past 5 years?
SUDEEPPHRM has achieved 5-year growth rates of: Sales Growth 32.48%, Profit Growth 50.39%, and EPS Growth -35.52%.
What is the promoter holding in SUDEEPPHRM and why does it matter?
Promoters hold 76.15% of SUDEEPPHRM shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Sudeep Pharma.
What is SUDEEPPHRM market capitalisation category?
SUDEEPPHRM has a market capitalisation of ₹8230 crores, placing it in the Mid-cap category.
How volatile is SUDEEPPHRM stock?
SUDEEPPHRM has a beta of N/A. A beta > 1 suggests the Sudeep Pharma stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is SUDEEPPHRM operating profit margin trend?
SUDEEPPHRM has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.
How is SUDEEPPHRM quarterly performance?
Recent quarterly performance shows Sudeep Pharma YoY Sales Growth of N/A% and YoY Profit Growth of N/A%.
What is the institutional holding pattern in SUDEEPPHRM?
SUDEEPPHRM has FII holding of 1.54% and DII holding of 14.76%. Significant institutional holding often suggests professional confidence in the Sudeep Pharma stock.